A treatment with synthetic antibodies developed by “Regeneron” reduced the risk of developing Covid with symptoms by more than 80 percent up to 8 months after receiving it, the American pharmaceutical company announced Monday.
The results are “especially important for people who do not respond to vaccines against COVID-19, including those who are immunocompromised,” said Myron Cohen, a researcher at the University of North Carolina who is leading a government-sponsored study on the treatment.
The study included 842 people who received a placebo and 841 people who received the treatment known as “Regine-Cove” at a dose of 1200 mg by injection under the skin.
During the follow-up period of two to eight months, there were 7 cases of COVID-19 in the treatment group and 38 in the placebo group, representing a reduction in the risk of developing an epidemic by 81.6 percent.
More importantly, there were no cases that required hospitalization in the treatment group, while 6 people were hospitalized in the placebo group.
“A single dose of Regen-Cove provides long-term protection against Covid-19, including when the risk is particularly high from household exposure, and in the long-term with continued exposure on a larger scale,” explained George Yankopoulos, the company’s president and chief scientific officer.
Regen-Cove has been approved in the United States as a preventive treatment for individuals who have been exposed to the disease and is pending full approval.
This treatment is based on two monoclonal antibodies produced in the laboratory, which are proteins that bind to the spines that spread on the surface of the Corona virus, preventing the pathogen from invading human cells.
.